First-in-class therapeutics or novel therapeutic mechanisms with curative potential for inheritable blood and bleeding disorders
Novel, precision diagnostics that have the potential to transform clinical practice by enabling earlier or more accurate diagnoses and closing health equity gaps
Novel technologies that have the potential to revolutionize treatment of inheritable blood and bleeding disorders or to disrupt the conventional care delivery model in ways that significantly close equity gaps
To ensure the long-term health of the Fund and the realization of its mission, P2C adopts industry standard investment considerations generally accepted and used by venture capital.
P2C makes equity investments traditionally but is open to a wide array of investment structures
All investment opportunities are strictly confidential. Opportunities will be reviewed internally to ensure mission focus and strategic alignment
P2C adopts and abides by the general venture capital industry standards when conducting the diligence process